Fernit..... you forget one thing.
With a new drug treating a previously untreated disease, of course there needs to be a comparison, 'the control', to show the efficacy of said new drug/treatment.
However stroke has been with us for a long long time so the control has been studied also for that very long long time. The medical professionals knows the timescales, improvement cycles and markers for untreated or currently available treatment for recovery from stroke...... That's their control.
If afamelanotide reduces that timescale and/or improves the recovery, then that is a win in my view.
In other words, they already have decades of 'control' patients.
GLA
Fernit..... you forget one thing. With a new drug treating a...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
-0.100(0.65%) |
Mkt cap ! $765.0M | |||
| Open | High | Low | Value | Volume |
| $15.34 | $15.35 | $15.02 | $660.2K | 43.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 238 | $15.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.40 | 238 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |